Merck's Soaring P/E Masks Patent Cliffs and Pipeline Setbacks, Triggering Institutional Exit

Related Articles

Why Are Emerging Markets Suddenly Soaring

4 months ago

What is BioFuel Dynamics' New Patent and Why Does it Matter

2 months ago

Is Big Pharma's Patent Cliff Driving a New M&A Wave

3 months ago

What Do Cleveland-Cliffs' Q1 2026 Results Really Tell Us

2 months ago

Category

You may also like

Stock News•1 week ago

Merck & Company (MRK) Price Forecast: Can Momentum Drive New Highs?

Merck (MRK) extended its bullish breakout from a pennant pattern on strong volume and higher swing lows, with technical structure pointing toward continued upside potential.

MRK

Share

Stock News•4 weeks ago

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK acquired Nuvalent for $10.6 billion, ending a mid-cap biotech M&A drought. The deal targets Nuvalent's pipeline to offset GSK's looming patent cliff losses.

GSK

Share

Stock News•1 months ago

Merck: Navigating the Patent Cliff and Future Growth Prospects

Merck (MRK) shares rose 4.79% following a discussion by contributing analysts regarding the company's patent cliff and future growth prospects. The segment highlights market trends and potential inves...

MRK

Share

Stock News•2 months ago

Merck's LOE Risks Mitigated - R&D And M&As Are Paying Off

Merck lowered its FY2026 adjusted EPS guidance due to IPR&D charges from two recent acquisitions. Despite this, the company remains on track to exceed $70B in annual revenue by the mid-2030s, supporte...

MRK

Share